Alternatives to Salmeterol for Asthma and COPD Management

Introduction to Alternatives

The American Thoracic Society recommends formoterol as a primary alternative to salmeterol, offering equivalent 12-hour bronchodilation with rapid onset of action, suitable for maintenance and reliever therapy in asthma when combined with inhaled corticosteroids (ICS) 1, 2

The National Asthma Education and Prevention Program suggests formoterol is the other available LABA with a duration of action exceeding 12 hours, administered twice daily via inhalation, and must always be combined with ICS due to the FDA black-box warning regarding increased risk of severe exacerbations and deaths with LABA monotherapy 2
The American Academy of Allergy, Asthma, and Immunology recommends leukotriene receptor antagonists (LTRAs) such as montelukast and zafirlukast as alternative adjunctive therapy with ICS for youths ≥12 years and adults, although they are less effective than LABAs when added to ICS 1, 3
The American College of Chest Physicians suggests sustained-release theophylline as an alternative adjunctive therapy with ICS for patients ≥5 years old, providing mild to moderate bronchodilation with possible mild anti-inflammatory effects, but requires serum theophylline concentration monitoring 1, 4
The European Respiratory Society recommends zileuton (5-lipoxygenase inhibitor) as an alternative adjunctive therapy in adults only, with mandatory liver function tests 1
The American Thoracic Society recommends omalizumab (anti-IgE) for patients ≥12 years with allergen sensitivity requiring step 5-6 care, with critical preparation for anaphylaxis treatment 1, 3

The Global Initiative for Chronic Obstructive Lung Disease recommends formoterol as a direct LABA alternative, providing comparable overall efficacy to salmeterol in improving lung function and controlling COPD symptoms 6
The American College of Chest Physicians suggests long-acting muscarinic antagonists (LAMAs) have shown greater effect on reducing COPD exacerbations compared to LABAs, with available LAMAs providing once-daily dosing 6, 7
The European Respiratory Society recommends LABA + LAMA combinations as a standard pharmacological strategy for COPD, providing additive bronchodilation through complementary mechanisms 7
The American Thoracic Society suggests ICS + LABA combinations are reserved for specific COPD phenotypes, such as FEV₁ <50% predicted with ≥2 exacerbations per year, and should be considered in patients with asthma-COPD overlap syndrome or sputum eosinophilia 7

The National Asthma Education and Prevention Program recommends choosing between formoterol and salmeterol based on rapid onset of action, allowing formoterol to be used in SMART (Single Maintenance and Reliever Therapy) approach for asthma at steps 3-4 8
The American Academy of Allergy, Asthma, and Immunology suggests avoiding common pitfalls such as using LABA as monotherapy for asthma, and instructing patients to use short-acting beta-agonists (SABA) for acute symptom relief, not their LABA inhaler 2